Symbols

INCY

Incyte·NASDAQ

--(--)

Signals Analysis

Bullish signal 3

Bearish signal 2

Ample Liquidity

High Gross Profit Margin

High Cash/net Profit Ratio

EPS Below Expectations

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About INCY

Incyte Corporation

A global biopharmaceutical company that develops small molecule drugs to treat cancer and inflammatory diseases

Industry

Biological Technology

Established Date

Listing Date

11/04/1993

Exchange

NASDAQ Stock Exchange

Full-time Employees

2,844

Fiscal Year Ends

12-31

Website

www.incyte.com

Security Type

Common stock

Office address

1801 Augustine Cut-Off, Wilmington, DE 19803

Business

Introduction

Incyte Corporation was incorporated in Delaware in 1991. The Company is a global biopharmaceutical company engaged in the discovery, development and commercialization of proprietary therapies. Its research and commercial efforts focus on three therapeutic areas: hematology, oncology, inflammation and autoimmunity.

Company Financials

EPS

INCY has released its 2025 Q4 earnings. EPS was reported at 1.8, versus the expected 1.91, missing expectations. The chart below visualizes how INCY has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

INCY has released its 2025 Q4 earnings report, with revenue of 1.51B, reflecting a YoY change of 27.84%, and net profit of 299.28M, showing a YoY change of 48.74%. The Sankey diagram below clearly presents INCY's revenue sources and cost distribution.